Received Jun 4, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
Suspected vaccination failure; got the shingles five days before Christmas; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a male patient who received Herpes zoster (Shingrix) solution for injection for prophylaxis. In NOV-2025, the patient received Shingrix. In DEC-2025, between 1 and 2 months after receiving Shingrix, the patient experienced vaccination failure (Verbatim: Suspected vaccination failure) (serious criteria GSK medically significant) and shingles (Verbatim: got the shingles five days before Christmas). The outcome of the vaccination failure was unknown and the outcome of the shingles was resolved. The reporter considered the vaccination failure and shingles to be related to Shingrix. The company considered the vaccination failure to be unrelated to Shingrix. The company considered the shingles to be related to Shingrix. Additional Information: GSK Receipt Date:31-MAY-2026 This case was reported by a patient via interactive digital media. The patient had received the vaccine a couple of days before holiday and then developed shingles five days before Christmas. He stated that the shot brought the shingles. He noted that it took a long time to get rid of them. The patient also expressed that he would not have developed shingles if he had not received the vaccine and advised others to take the vaccine at their own risk. This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule and laboratory confirmation regarding shingles were unknown at the time of reporting. The batch number was not provided, and we are unable to contact the reporter.; Sender's Comments: A case of Vaccination failure, between 1 and 2 months after receiving Shingrix, in a male patient. Based on the available information a possible causality that the event was caused by the GSK product cannot be ascertained. Consent for further follow-up has not been received.